Eschewing the traditional path of receptor-targeted drugs - which usually requires disease characterization by specific cellular markers - D-Pharm has created RAP (regulated activation of prodrugs), a technology that enables the selective activation and accumulation of drugs within a disease site without the necessity of known markers.

The company believes that the selective metabolic activation of RAP-modified prodrugs within diseased cells enables a significant reduction of a drug's effective doses accompanied by a reduction of toxicity and improved therapeutic benefit.